Sun Pharma Adv. Res

₹219.3 6.8 | 3.2%

WEBSITE BSE:532872 NSE : SUNPHA ADV 10 May, 16:01

Market Cap ₹7115 Cr.

Stock P/E -19.6

P/B 30.7

Current Price ₹219.3

Book Value ₹ 7.2

Face Value 1

52W High ₹474

Dividend Yield 0%

52W Low ₹ 178.1

Edit Ratio

Sun Pharma Adv. Res Research see more...

Overview Inc. Year: 2006Industry: Business Support

Sun Pharma Advanced Research Company Ltd is engaged in the research and development on natural sciences and engineering (Pharmacy). The Company operates via Pharmaceuticals Research & Development section. Its programs consist of Xelpros, Elepsia XR, Baclofen GRS, Paclitaxel Injection Concentrate for Nanodispersion (Taclantis), Salmeterol - Fluticasone Dry Powder Inhaler (DPI), SUN-K706, Brimonidine OD, Tizanidine ER, Minocycline Topical and SUN-597 Topical. Xelpros is a Benzalkonium Chloride (BAK)-free Latanoprost eye drops developed with its Swollen Micelle Microemulsion (SMM) generation. Elepsia XR is a once-a-day method of Levetiracetam, an antiepileptic agent. Baclofen GRS is a once-a-day formula of Baclofen, a centrally acting, antispasmodic drug. Taclantis is a Cremophor and Albumin free method. Its DPI is a premetered, 60 doses, breath activated tool to manage combination of Salmeterol and Fluticasone by way of inhalation.

Sun Pharma Adv. Res Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Sun Pharma Adv. Res Quarterly Results

#(Fig in Cr.)	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023
Net Sales	22	28	22	28	62	28	32	131	48	24
Other Income	2	0	1	5	0	0	0	0	11	10
Total Income	23	28	23	33	62	29	32	131	58	34
Total Expenditure	85	78	76	83	73	107	94	115	137	126
Operating Profit	-61	-50	-53	-49	-11	-78	-63	16	-79	-92
Interest	4	4	5	3	2	2	3	3	0	0
Depreciation	3	3	3	3	3	3	3	3	3	3
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	-68	-57	-61	-55	-16	-82	-68	10	-82	-95
Provision for Tax	0	0	0	0	0	0	0	0	0	0
Profit After Tax	-68	-57	-61	-55	-16	-82	-68	10	-82	-95
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	-68	-57	-61	-55	-16	-82	-68	10	-82	-95
Adjusted Earnings Per Share	-2.6	-2.2	-2.3	-2.1	-0.6	-3	-2.5	0.4	-2.5	-2.9

Sun Pharma Adv. Res Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	87	167	156	161	181	78	183	77	253	137	239	235
Other Income	2	10	3	3	14	5	14	10	5	7	11	21
Total Income	89	177	159	164	195	83	196	87	258	144	250	255
Total Expenditure	104	134	191	224	304	321	334	387	388	324	453	472
Operating Profit	-15	43	-32	-60	-109	-238	-138	-300	-130	-180	-203	-218
Interest	4	6	0	2	2	0	0	3	11	13	8	6
Depreciation	3	4	7	8	8	8	8	9	11	10	12	12
Exceptional Income / Expenses	0	0	0	0	0	49	0	0	0	0	0	0
Profit Before Tax	-22	34	-40	-70	-119	-197	-145	-312	-151	-203	-223	-235
Provision for Tax	0	4	0	0	0	0	0	0	0	0	0	0
Profit After Tax	-22	30	-40	-70	-119	-197	-145	-312	-151	-203	-223	-235
Adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	-22	30	-40	-70	-119	-197	-145	-312	-151	-203	-223	-235
Adjusted Earnings Per Share	-0.9	1.3	-1.7	-3	-4.8	-7.9	-5.5	-11.9	-5.8	-7.5	-6.9	-7.5

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	74%	46%	25%	11%
Operating Profit CAGR	0%	0%	0%	0%
PAT CAGR	0%	0%	0%	0%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	12%	-0%	7%	4%
ROE Average	-144%	-48%	-89%	-87%
ROCE Average	-69%	-183%	-158%	-99%

Sun Pharma Adv. Res Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	108	139	100	32	158	185	296	-19	-168	31	513
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	4	4	3	3	2	2	1	6	113	0	0
Other Non-Current Liabilities	2	6	6	7	8	10	6	49	52	77	138
Total Current Liabilities	94	39	37	125	108	116	95	235	233	171	179
Total Liabilities	209	188	147	167	277	313	398	273	230	280	830
Fixed Assets	66	64	67	70	69	52	58	104	91	92	106
Other Non-Current Assets	4	12	17	29	49	86	84	102	76	117	269
Total Current Assets	139	110	63	67	158	175	257	67	60	71	455
Total Assets	209	188	147	167	277	313	398	273	230	280	830

Sun Pharma Adv. Res Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	1	0	0	11	4	64	0	0	0	9	1
Cash Flow from Operating Activities	-95	37	-41	-44	-128	-183	-172	-211	-152	-208	-69
Cash Flow from Investing Activities	-99	44	53	-13	-7	-105	-102	155	2	-29	-548
Cash Flow from Financing Activities	194	-81	-1	51	194	224	274	55	159	229	617
Net Cash Inflow / Outflow	-0	-0	11	-7	60	-63	0	0	9	-8	-1
Closing Cash & Cash Equivalent	0	0	11	4	64	0	0	0	9	1	1

Sun Pharma Adv. Res Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	-0.94	1.27	-1.66	-2.96	-4.82	-7.85	-5.55	-11.92	-5.77	-7.48	-6.86
CEPS(Rs)	-0.8	1.42	-1.35	-2.64	-4.49	-7.52	-5.26	-11.56	-5.35	-7.11	-6.5
DPS(Rs)	0	0	0	0	0	0	0	0	0	0	0
Book NAV/Share(Rs)	4.52	5.82	4.18	1.21	6.41	3.71	11.3	-0.71	-6.42	-7.47	15.8
Core EBITDA Margin(%)	-19.21	20.05	-22.54	-39.18	-67.78	-310.01	-82.73	-403.58	-53.36	-136.07	-89.65
EBIT Margin(%)	-21.25	23.9	-25.24	-42.06	-64.75	-251.57	-79.48	-403.22	-55.54	-138.48	-90.02
Pre Tax Margin(%)	-25.77	20.55	-25.38	-43.4	-65.76	-251.73	-79.53	-406.7	-59.75	-148.19	-93.22
PAT Margin (%)	-25.77	18.15	-25.38	-43.4	-65.76	-251.73	-79.53	-406.7	-59.75	-148.19	-93.22
Cash Profit Margin (%)	-21.88	20.29	-20.73	-38.7	-61.21	-241.27	-75.4	-394.36	-55.43	-140.79	-88.29
ROA(%)	-15.27	15.29	-23.65	-44.68	-53.72	-66.85	-40.89	-93.11	-60.18	-79.8	-40.1
ROE(%)	-110.94	24.62	-33.17	-109.16	-127.4	-156.84	-74.72	-225.08	0	0	-143.72
ROCE(%)	-19.55	24.02	-31.74	-71.37	-94.66	-113.05	-59.95	-178.95	-254.1	-225.57	-69.44
Receivable days	61.31	57.97	56.11	32.87	48.45	131.66	27.67	62.28	24.26	60.25	46.2
Inventory Days	0	0	0	0	0	0	0	0	0	0	0
Payable days	0	0	0	0	0	0	0	0	0	0	0
PER(x)	0	113.8	0	0	0	0	0	0	0	0	0
Price/Book(x)	25	24.87	116.99	237.33	49.44	102.03	16.98	-135.68	-22.07	-39.75	11.36
Dividend Yield(%)	0	0	0	0	0	0	0	0	0	0	0
EV/Net Sales(x)	31.67	20.65	74.67	42.52	42.82	121.33	27.52	33.79	15.55	59.34	23.92
EV/Core EBITDA(x)	-182.48	79.31	-362.71	-113.82	-71.13	-39.95	-36.52	-8.64	-30.37	-45.27	-28.11
Net Sales Growth(%)	201.21	91.37	-6.76	3.56	12.24	-56.77	133.67	-57.99	229.31	-45.74	73.98
EBIT Growth(%)	74.23	315.28	-198.45	-72.6	-72.8	-67.96	26.18	-113.11	54.64	-35.29	-13.09
PAT Growth(%)	68.86	234.81	-230.32	-77.11	-70.07	-65.49	26.18	-114.81	51.62	-34.58	-9.43
EPS Growth(%)	72.28	234.76	-230.32	-78.33	-63.04	-62.83	29.31	-114.81	51.62	-29.71	8.32
Debt/Equity(x)	0.75	0.04	0.04	1.94	0.02	0.02	0.01	-3.59	-1.37	-0.37	0
Current Ratio(x)	1.48	2.84	1.69	0.53	1.47	1.51	2.71	0.29	0.26	0.42	2.54
Quick Ratio(x)	1.48	2.84	1.69	0.53	1.47	1.51	2.71	0.29	0.26	0.42	2.54
Interest Cover(x)	-4.69	7.13	-180.04	-31.45	-64.41	-1596.71	-1547.78	-115.79	-13.19	-14.26	-28.15
Total Debt/Mcap(x)	0.03	0	0	0.01	0	0	0	0.03	0.06	0.01	0

Sun Pharma Adv. Res Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	68.1	69.09	69.09	69.09	68.22	65.67	65.67	65.67	65.67	65.67
FII	2.51	2.38	2.4	2.38	3.48	3.64	3.64	3.67	3.3	3.23
DII	0.55	0.76	0.76	0.76	0.76	0.63	0.64	0.66	0.67	0.67
Public	28.84	27.77	27.75	27.77	27.54	30.06	30.06	30	30.36	30.42
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	17.94	18.78	18.78	18.78	18.78	21.31	21.31	21.31	21.31	21.31
FII	0.66	0.65	0.65	0.65	0.96	1.18	1.18	1.19	1.07	1.05
DII	0.15	0.21	0.21	0.21	0.21	0.21	0.21	0.21	0.22	0.22
Public	7.6	7.55	7.55	7.55	7.58	9.75	9.75	9.74	9.85	9.87
Others	0	0	0	0	0	0	0	0	0	0
Total	26.35	27.19	27.19	27.19	27.53	32.45	32.45	32.45	32.45	32.45

Pros

Company is almost debt free.

Cons

Company has a low return on equity of -48% over the last 3 years.
Stock is trading at 30.7 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Sun Pharma Adv. Res News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Sun Pharma Adv. Res

Add Watchlist

Sun Pharma Adv. Res Research see more...

Overview Inc. Year: 2006Industry: Business Support

Sun Pharma Adv. Res Share Price

Alert Data

Quarterly Price

Peer Comparison

Sun Pharma Adv. Res Quarterly Results

Sun Pharma Adv. Res Profit & Loss

Growth Rates

Sun Pharma Adv. Res Balance Sheet

Sun Pharma Adv. Res Cash Flow

Sun Pharma Adv. Res Ratios

Sun Pharma Adv. Res Shareholding Pattern

Sun Pharma Adv. Res News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!